Uterine cancer

Uterine cancer (or endometrial carcinoma) is a malignant tumour of the lining of the uterus. Women in the climacteric period are affected mostly after the menopause. Only about five percent are younger than 40 years old. In Western countries, uterine cancer occurs twice as often as cervical cancer. The rate of new cases per year has increased in recent years–it now stands at 25 in 100,000 women.

Early cancers can rarely be noticed in the context of screening. This tumour is noticeable early due to bleeding. Bleeding is always suspicious after the menopause, as is irregular with flesh-coloured discharge. Associated abdominal pain almost always indicates a far advanced, inoperable tumour.

It is believed that having an elevated oestrogen level for many years stimulates tumour formation; for example, women with cycle disorders, late menopause and hormone replacement therapy have a higher risk than the population average. Obesity, high blood pressure and diabetes mellitus II increase the tumour risk. It is well known that obesity increases oestrogen production. Any risk linked to the exposure to phytoestrogens (oestrogen-like substances in food) is so far unclear. However, it is thought that hormone therapy with oestrogen increases the risk.

To diagnose uterus carcinoma, an ultrasound, computer tomography, magnetic resonance imaging, hysteroscopy (endoscopy of the uterus) or a tissue extraction (curettage) is performed. The diagnosis is confirmed by a scraping of the uterus.

Recommended therapies for the treatment of uterine cancer:

Whole body Hyperthermia

The healing effect of whole-body hyperthermia for patients with uterine carcinoma is that we can very quickly bring the body to high temperatures (up 40.5 °). This fast and high heating activates not only the immune system, but many degenerate cells of the uterine are destroyed by the fast floods of heat. In addition to the damage or removal of the cancer cells, the whole-body hyperthermia stimulates the immune system significantly without impacting the rest of the body. It triggers an immune cascade that activates and multiplies the white blood cells.

Locoregional Hyperthermia

The regional effective hyperthermia is also advisable for uterine cancer: during this treatment the affected region is quickly heated to high temperatures (40 up to 44 ° C). This heat activates the immune system. Many degenerated cells of the Uterine tissue will be harmed or destroyed. In our day clinic at the Hyperthermia Centre Hannover we offer the partial body hyperthermia depending on the diagnosis, in which only damaged or degenerated tissue is overheated, which guarantees very gentle treatment to our patients.

IPT - Low Dose Chemotherapy

Patients with a uterine carcinoma can be successfully treated at the Hyperthermia Centre Hanover with IPT Insulin potentiation therapy, which uses the hormone insulin to inject drugs more effectively in the tumour cells. Because the degenerate cells of the Uterine tissue have a higher basal metabolic rate than normal cells, they attempt to absorb sugar more quickly after a period of low blood sugar. The mechanism is via so-called insulin receptors. Because tumour cells in the Uterine have in general more of the so-called ‘insulin receptors’ than normal cells, chemotherapy can therefore impact the malignant cells more effectively. As a result the dosage of conventional chemotherapy protocols can be reduced, and thus the side effects can also be significantly lowered.


For patients with uterus cancer the healing-promoting effect of oncolytic virotherapy is destroying the cancer cells using viruses. The Virotherapy consists of several injections according to a predetermined Virotherapie protocol, In the hyperthermia Centre Hannover will conduct with Dr. Mohamed Ali Zayen as certified specialists of Virotherapy RIGVIR®. A Virotherapy is outpatient and after an individually tailored treatment plan. The interval of RIGVIR® injection is different from protocol to an other.